Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome (2012)

  • Authors:
  • USP affiliated authors: VIANA, VILMA DOS SANTOS TRINDADE - FM ; BUENO, CLEONICE - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
  • USP Schools: FM; FM; FM
  • DOI: 10.1007/s10067-012-2019-z
  • Subjects: ACIDENTE VASCULAR CEREBRAL; SÍNDROME DE SJOGREN; TROMBOSE
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s10067-012-2019-z (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Versões disponíveis em Acesso Aberto do: 10.1007/s10067-012-2019-z (Fonte: Unpaywall API)

    Título do periódico: Clinical Rheumatology

    ISSN: 0770-3198,1434-9949



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: Clinical Rheumatology

    ISSN: 0770-3198

    Citescore - 2017: 2.04

    SJR - 2017: 0.93

    SNIP - 2017: 0.877


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2313564-10BCSEP 011 2012
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      PASOTO, Sandra Gofinet; CHAKKOUR, Henrique Pires; NATALINO, Renato Romera; et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome. Clinical rheumatology, Brussels, n. 9, p. 1331-1338, 2012. Disponível em: < http://www.springerlink.com/content/1272g8v34xq23677/fulltext.pdf > DOI: 10.1007/s10067-012-2019-z.
    • APA

      Pasoto, S. G., Chakkour, H. P., Natalino, R. R., Viana, V. S. T., Bueno, C., Lianza, A. C., et al. (2012). Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome. Clinical rheumatology, ( 9), 1331-1338. doi:10.1007/s10067-012-2019-z
    • NLM

      Pasoto SG, Chakkour HP, Natalino RR, Viana VST, Bueno C, Lianza AC, Andrade JL de, Levy Neto M, Fuller R, Bonfá E. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome [Internet]. Clinical rheumatology. 2012 ;( 9): 1331-1338.Available from: http://www.springerlink.com/content/1272g8v34xq23677/fulltext.pdf
    • Vancouver

      Pasoto SG, Chakkour HP, Natalino RR, Viana VST, Bueno C, Lianza AC, Andrade JL de, Levy Neto M, Fuller R, Bonfá E. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome [Internet]. Clinical rheumatology. 2012 ;( 9): 1331-1338.Available from: http://www.springerlink.com/content/1272g8v34xq23677/fulltext.pdf

    Referências citadas na obra
    Tzioufas AG, Voulgarelis M (2007) Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 21:989–1010
    Amarasena R, Bowman S (2007) Sjögren’s syndrome. Clin Med 7:53–56
    Routsias JG, Tzioufas AG (2007) Sjögren’s syndrome—study of autoantigens and autoantibodies. Clinic Rev Allerg Immunol 32:238–251
    Asherson RA, Fei HM, Staub HL, Khamashta MA, Hughes GR, Fox RI (1992) Antiphospholipid antibodies and HLA associations in primary Sjögren's syndrome. Ann Rheum Dis 51:495–498
    Jedryka-Goral A, Jagiello P, D'Cruz DP et al (1992) Isotype profile and clinical relevance of anticardiolipin antibodies in Sjögren's syndrome. Ann Rheum Dis 51:889–891
    Cervera R, García-Carrasco M, Font J et al (1997) Antiphospholipid antibodies in primary Sjögren’s syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol 15:361–365
    Katayama Y, Kohriyama K, Kirizuka K, Nishizaki H, Fujii H, Tanji Y (2000) Sjögren’s syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome. Intern Med 39:6–7
    Ulvestad E, Kanestrom A, Tengnér P, Gjerde S, Sundal J, Haga HJ (2000) Anti-cardiolipin autoantibodies and pulmonary embolism. A case for a common cause. Scand J Rheumatol 29:330–333
    Wielosz E, Majdan M, Koszamy A, Zychowska I (2007) The overlap of primary Sjögren’s syndrome with antiphospholipid syndrome in man: case report. Pol Arch Med Wewn 117:76
    Fauchais A-L, Lambert M, Launay D et al (2004) Antiphospholipid antibodies in primary Sjögren’s syndrome: prevalence and clinical significance in a series of 74 patients. Lupus 13:245–248
    Petri M (2000) Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 15:145–151
    García-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Med 81:270–280
    Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311
    Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306
    Haga HJ, Jacobsen EM, Peen E (2008) Incidence of thromboembolic events in patients with primary Sjögren's syndrome. Scand J Rheumatol 37:127–129
    Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 69:1103–1109
    Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558
    Galanaud JP, Bosson JL, Quéré I (2011) Risk factors and early outcomes of patients with symptomatic distal vs. proximal deep-vein thrombosis. Curr Opin Pulm Med 17:387–391
    Sanz J, Fuster V (2011) The year in atherothrombosis. J Am Coll Cardiol 58:779–791
    Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61:29–36
    Pierangeli SS, Harris EN (2005) Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 357:17–33
    Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC, Standardization group of the European Forum on Antiphospholipid Antibodies (2004) Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2:1860–1862
    Wisloff F, Jacobsen EM, Liestol S (2002) Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 108:263–271
    Esparza RH, Swaak T, Aarden L, Smeenk R (1985) Complement-fixing antibodies to dsDNA detected by the immunofluorescence technique on Crithidia luciliae. A critical appraisal. J Rheumatol 12:1109–1117
    Mahler M, Stinton LM, Fritzler MJ (2005) Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of a SmD3 peptide-based immunoassay. Clin Diagn Lab Immunol 12:107–113
    Ruiz-Tíscar JL, López-Longo FJ, Sánchez-Ramón S et al (2005) Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. Ann N Y Acad Sci 1050:210–216
    Goeldner I, Skare TL, de Messias Reason IT, Nisihara RM, Silva MB, Utiyama SR (2010) Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology (Oxford) 49:1590–1593
    Bakker AJ, Slomp J, de Vries T et al (2003) Adequate sampling in cryoglobulinaemia: recommended warmly. Clin Chem Lab Med 41:85–89
    Juby AG, Davis P (1998) Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 21:4–11
    Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN (1990) Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 20:231–236
    Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9:A299–A304
    Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8:998–1005
    Theander E, Jacobsson LT (2008) Relationship of Sjögren’s syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am 34:935–947
    Palomo I, Segovia F, Ortega C, Pierangeli S (2009) Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol 27:668–677
    Ramos-Casals M, Nardi N, Brito-Zerón P et al (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35:312–321
    Ramírez M, Ramos-Casals M, Graus F (2009) Central nervous system involvement in primary Sjögren syndrome. Med Clin (Barc) 133:349–359
    Delalande S, de Seze J, Fauchais AL et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83:280–291
    He J, Guo JP, Ding Y et al (2011) Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren's syndrome. Rheumatology (Oxford) 50:879–884